A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis

• To evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis patients
• To evaluate the safety of rebamipide as an adjuvant regimen in erosive reflux esophagitis (ERE)

Inclusion criteria

• Male/female patients aged 20 to 70 at the time of writing an informed consent.
• Subjects who were diagnosed with Erosive Reflux Esophagitis (ERE) using Los Angeles (LA) classification grade A~D, confirmed by endoscopy.
• The subjects regardless of presence of ERE symptom (i.e., symptomatic ERE or asymptomatic ERE).

For symptomatic ERE, the subject must have one or more symptoms of the followings: acid regurgitation, heartburn, epigastric pain, cough, hoarseness, globus pharyngis, atypical chest pain.

• Subjects who have consented to participate in this clinical study by signing an informed consent form.

Exclusion criteria

• Patients with known hypersensitivity to any component of Lanston® and/or Mucosta® formulations.
• Other concurrent organic upper gastroesophageal disease in endoscopy (i.e., drug-induced esophagitis, viral esophagitis, Mallory-Weiss syndrome, peptic ulcer disease, malignancies) and patients who was diagnosed with Barrett's esophagus.
• History of abdominal surgery that can affect gastrointestinal motility (except appendectomy and hysterectomy).
• History of upper gastrointestinal bleeding or obstruction.
• Patients administrated with any drugs that can affect the efficacy of study regimen (proton pump inhibitors, revaprazan, prokinetics, H2-blockers, etc.) within 2 weeks (however, 4 weeks for PPIs) prior to enrollment and/or those who are required of NSAIDs, anti-coagulants, anti-cholinergics, prostaglandin E, corticosteroids, and anti-depressants treatment during the study period.
• History of pancreatobiliary disease (except asymptomatic gallbladder stone), inflammatory bowel disease, cirrhotic liver disease, chronic kidney disease.
• Pregnant, nursing, and childbearing potential women who is unwilling to effective contraception; for example, oral contraceptives, hormonal methods, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilization, and true abstinence.
• History of psychological disorder, alcoholics, and drug abuser.
• Blood test results of hemoglobin (Hb) ≤ 10.0 g/dL, platelets ≤ 50,000 /µL, total WBCs ≤ 4,000/µL or ≥ 10,000/µL, and with serum test results showing the levels of AST, ALT, ALP, BUN, and creatinine exceeding twice the normal range of respective institution.
• Patients who previously underwent another clinical survey within 4 weeks.
• History of major medical disease that can affect general condition and other patients deemed not eligible for this study by investigators.